Department of Epidemiology and Biostatistics, College of Public Health, University of South Florida, Tampa, FL, United States of America.
Tisch Cancer Institute, Icahn School of Medicine, Mount Sinai School of Medicine, New York, NY, United States of America.
PLoS One. 2018 Jul 11;13(7):e0199745. doi: 10.1371/journal.pone.0199745. eCollection 2018.
To evaluate improvement in survival of lymphoma patients from 1990 to 2014, stratified by age, sex and race using Surveillance Epidemiology and End-Result Survey Program (SEER) data.
We identified 113,788 incident lymphoma cases from nine SEER cancer registries were followed up for cause-specific mortality from lymphoma. Cox proportional hazard regression was used to estimate hazard ratios (HRs) and their respective 95% confidence interval (CIs) for various time periods within groups stratified by race, age and sex.
Five-year survival for Hodgkin's lymphoma (HL) was 89% for patients 20-49 years of age. For this age group, compared to 1990-1994, survival significantly improved in 2000-2004 (HR = 0.65; 95% CI: 0.54-0.78), 2005-2009 (HR = 0.46, 95% CI: 0.38-0.57) and 2010-2014 (HR = 0.29, 95% CI: 0.20-0.41). Hodgkin's lymphoma patients aged 75-85 years had 5-year survival of 37% and in these patients, compared to 1990-1994, survival only improved from 2005 onward (HR = 0.67, 95% CI: 0.50-0.90). In patients with non-Hodgkin's Lymphoma (NHL), all age groups showed survival improvements between 1990-1994 period and 2010-2014 period. Improvements in HL and NHL survival were seen for all race categories and both genders.
Survival among US lymphoma patients has improved substantially between 1990-1994 period and 2010-2014 period, though disease-specific mortality was still higher in older age groups.
利用监测、流行病学和最终结果调查计划(SEER)的数据,按年龄、性别和种族对 1990 年至 2014 年淋巴瘤患者的生存率进行分层评估。
我们从九个 SEER 癌症登记处确定了 113788 例淋巴瘤新发病例,随访了这些患者的淋巴瘤特异性死亡原因。采用 Cox 比例风险回归估计了不同种族、年龄和性别亚组内不同时间段的风险比(HR)及其各自的 95%置信区间(CI)。
20-49 岁霍奇金淋巴瘤(HL)患者的 5 年生存率为 89%。对于该年龄组,与 1990-1994 年相比,2000-2004 年(HR=0.65;95%CI:0.54-0.78)、2005-2009 年(HR=0.46,95%CI:0.38-0.57)和 2010-2014 年(HR=0.29,95%CI:0.20-0.41)生存率显著提高。75-85 岁霍奇金淋巴瘤患者的 5 年生存率为 37%,与 1990-1994 年相比,仅从 2005 年开始生存率有所提高(HR=0.67,95%CI:0.50-0.90)。非霍奇金淋巴瘤(NHL)患者中,所有年龄组在 1990-1994 年与 2010-2014 年期间生存率均有所提高。HL 和 NHL 生存率的提高在所有种族类别和性别中均可见。
1990-1994 年至 2010-2014 年期间,美国淋巴瘤患者的生存率有了显著提高,尽管年龄较大的患者的疾病特异性死亡率仍然较高。